Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 12/20 | 0.43 |
| ▸ | RAB9A | P51151 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | ABL1 | P00519 | 1/20 | 0.38 |
| ▸ | LDLR | P01130 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3058462 | 0.93 | MAPK14 (0.44) | MAPK14RAB9AMEN1KMT2ANPC1 | |
| SCHEMBL3042003 | 0.85 | NPC1 (0.46) | MAPK14RAB9AMEN1KMT2ANPC1 | |
| SCHEMBL5138721 | 0.84 | MAPK14 (0.47) | MAPK14RAB9AKMT2ANPC1CYP1A2 | |
| SCHEMBL4507706 | 0.82 | MAPK14 (0.57) | MAPK14RAB9AMEN1KMT2ANPC1 | |
| SCHEMBL3054278 | 0.79 | MAPK14 (0.59) | MAPK14RAB9ANPC1HPGDSMN1; SMN2 | |
| SCHEMBL3051000 | 0.78 | MAPK14 (0.48) | MAPK14RAB9AMEN1KMT2ANPC1 | |
| SCHEMBL3052171 | 0.77 | MAPK14 (0.49) | MAPK14 | |
| SCHEMBL27706475 | 0.75 | MAPK14 (0.43) | MAPK14RAB9AMEN1KMT2ANPC1 | |
| SCHEMBL3051662 | 0.74 | MAPK14 (0.47) | MAPK14RAB9ANPC1 | |
| SCHEMBL3061264 | 0.74 | MAPK14 (0.48) | MAPK14NPC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100222363-A1 | Bicyclic Derivatives as P38 Inhibitors | PALAU PHARMA, S.A. (ES) | 2010-09-02 | — | — | US | claimed |
| US-20100222363-A1 | Bicyclic Derivatives as P38 Inhibitors | PALAU PHARMA, S.A. (ES) | 2010-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222363-A1 | Bicyclic Derivatives as P38 Inhibitors | MAPK1, MAPKAPK2, MAPK7 | MAPK14 21/4885RAB9A 1460/4885MEN1 4549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.